FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151328241> ?p ?o ?g. }

• W2151328241 endingPage "195" @default.
• W2151328241 startingPage "186" @default.
• W2151328241 abstract "Summary We report the final results of a prospective multi‐centre trial testing the combination of chemotherapy (fludarabine, cytosine arabinoside and idarubicin; FLAI) followed by low‐dose gemtuzumab ozogamicin (GO), for induction treatment of patients with CD33+ acute myeloid leukaemia (AML). Forty‐six consecutive patients were treated: the median age was 66 (range: 60–80) years; the karyotype was unfavourable in 12 patients (26%), intermediate in 33 (71%) and favourable in one (3%). Eleven major infectious complications were recorded. There was one early death. Of the 45 evaluable patients, 24 achieved a complete response (CR; 52%), 66% and 33% in good‐intermediate/poor karyotype patients. Median duration of CR was 7 (3–24) months. The cumulative incidence of relapse was 37% with an actuarial 2‐year survival of 54%. These results were compared with 47 patients matched for age and karyotype who received FLAI, without GO. The proportion of patients achieving CR was comparable. However, patients with de novo AML receiving GO ( n = 26) had a significantly lower risk of relapse at 2 years when compared with patients not receiving GO ( n = 35) (40% vs. 80%, P = 0·01) and significantly better overall 2‐year survival (40% vs. 14% P = 0·02). Patients with secondary AML had comparable outcome whether or not they received GO. This GO‐based induction chemotherapy has a good toxicity profile. In keeping with a recent prospective randomised trial, the addition of GO seems to prolong disease‐free survival." @default.
• W2151328241 created "2016-06-24" @default.
• W2151328241 creator A5000633141 @default.
• W2151328241 creator A5003509028 @default.
• W2151328241 creator A5004633066 @default.
• W2151328241 creator A5007754732 @default.
• W2151328241 creator A5016794322 @default.
• W2151328241 creator A5020549562 @default.
• W2151328241 creator A5022984958 @default.
• W2151328241 creator A5033482554 @default.
• W2151328241 creator A5033747062 @default.
• W2151328241 creator A5048224601 @default.
• W2151328241 creator A5057540692 @default.
• W2151328241 creator A5067079961 @default.
• W2151328241 creator A5069969800 @default.
• W2151328241 creator A5078922292 @default.
• W2151328241 creator A5084040459 @default.
• W2151328241 creator A5086489839 @default.
• W2151328241 date "2007-06-22" @default.
• W2151328241 modified "2023-10-18" @default.
• W2151328241 title "Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients" @default.
• W2151328241 cites W1804439365 @default.
• W2151328241 cites W1857665725 @default.
• W2151328241 cites W1969474912 @default.
• W2151328241 cites W1970946990 @default.
• W2151328241 cites W1974804829 @default.
• W2151328241 cites W1977847184 @default.
• W2151328241 cites W1994003593 @default.
• W2151328241 cites W2007125021 @default.
• W2151328241 cites W2033269039 @default.
• W2151328241 cites W2045786291 @default.
• W2151328241 cites W2051440036 @default.
• W2151328241 cites W2054634308 @default.
• W2151328241 cites W2061960126 @default.
• W2151328241 cites W2065406906 @default.
• W2151328241 cites W2079799706 @default.
• W2151328241 cites W2080506962 @default.
• W2151328241 cites W2084486691 @default.
• W2151328241 cites W2094681262 @default.
• W2151328241 cites W2106260849 @default.
• W2151328241 cites W2136628941 @default.
• W2151328241 cites W2160768181 @default.
• W2151328241 cites W2169994420 @default.
• W2151328241 cites W2204518675 @default.
• W2151328241 cites W2318674152 @default.
• W2151328241 cites W2764775166 @default.
• W2151328241 cites W3082443879 @default.
• W2151328241 cites W4237543851 @default.
• W2151328241 cites W4237785786 @default.
• W2151328241 cites W4239564692 @default.
• W2151328241 cites W4242752547 @default.
• W2151328241 cites W4244897830 @default.
• W2151328241 cites W4312790597 @default.
• W2151328241 cites W4385970358 @default.
• W2151328241 doi "https://doi.org/10.1111/j.1365-2141.2007.06646.x" @default.
• W2151328241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17593025" @default.
• W2151328241 hasPublicationYear "2007" @default.
• W2151328241 type Work @default.
• W2151328241 sameAs 2151328241 @default.
• W2151328241 citedByCount "38" @default.
• W2151328241 countsByYear W21513282412012 @default.
• W2151328241 countsByYear W21513282412013 @default.
• W2151328241 countsByYear W21513282412014 @default.
• W2151328241 countsByYear W21513282412019 @default.
• W2151328241 countsByYear W21513282412020 @default.
• W2151328241 countsByYear W21513282412022 @default.
• W2151328241 crossrefType "journal-article" @default.
• W2151328241 hasAuthorship W2151328241A5000633141 @default.
• W2151328241 hasAuthorship W2151328241A5003509028 @default.
• W2151328241 hasAuthorship W2151328241A5004633066 @default.
• W2151328241 hasAuthorship W2151328241A5007754732 @default.
• W2151328241 hasAuthorship W2151328241A5016794322 @default.
• W2151328241 hasAuthorship W2151328241A5020549562 @default.
• W2151328241 hasAuthorship W2151328241A5022984958 @default.
• W2151328241 hasAuthorship W2151328241A5033482554 @default.
• W2151328241 hasAuthorship W2151328241A5033747062 @default.
• W2151328241 hasAuthorship W2151328241A5048224601 @default.
• W2151328241 hasAuthorship W2151328241A5057540692 @default.
• W2151328241 hasAuthorship W2151328241A5067079961 @default.
• W2151328241 hasAuthorship W2151328241A5069969800 @default.
• W2151328241 hasAuthorship W2151328241A5078922292 @default.
• W2151328241 hasAuthorship W2151328241A5084040459 @default.
• W2151328241 hasAuthorship W2151328241A5086489839 @default.
• W2151328241 hasBestOaLocation W21513282411 @default.
• W2151328241 hasConcept C10205521 @default.
• W2151328241 hasConcept C126322002 @default.
• W2151328241 hasConcept C141071460 @default.
• W2151328241 hasConcept C176290653 @default.
• W2151328241 hasConcept C188816634 @default.
• W2151328241 hasConcept C2776694085 @default.
• W2151328241 hasConcept C2776755627 @default.
• W2151328241 hasConcept C2778041864 @default.
• W2151328241 hasConcept C2778623314 @default.
• W2151328241 hasConcept C2779117419 @default.
• W2151328241 hasConcept C2779263901 @default.
• W2151328241 hasConcept C28328180 @default.
• W2151328241 hasConcept C54355233 @default.
• W2151328241 hasConcept C71924100 @default.

• next